Skip to main content
2026 CRT Conference Main banner

CRT 2026

Power Break Symposium

Session:: Power Break Symposium | Should We Be Doing More for STEMI Patients in the Cath Lab? (Prevention vs Palliation) [CME] – Supported Through an Educational Grant by Zoll TherOx

Final Thoughts & Panel Discussion

Sunday, March 8, 2026
1:15 PM - 1:30 PM EST
Location: Lincoln

    Moderator(s)

  • Timothy D. Henry, MD

    Director, The Carl and Edyth Lindner Center for Research and Education
    The Christ Hospital
    Bellevue, Kentucky, United States

    Disclosure(s): No financial relationships to disclose

    • Panel Discussant(s)

  • Jeff W. Chambers, MD, FSCAI, FACC

    Director of the percutaneous Coronary Interventions
    Metropolitian Heart and Vascular Institute
    Minneapolis, Minnesota, United States

    Disclosure(s): Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)

  • William F. Fearon, MD

    Professor of Medicine Director, Interventional Cardiology
    Stanford University School of Medicine
    Stanford, California, United States

    Disclosure information not submitted.

  • Michael J. Lim, MD

    Interventional Cardiologist
    Poplar Bluff Regional Medical Center
    Poplar Bluff, Missouri, United States

    Disclosure(s): Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)

  • Sandeep Nathan, MD, MSc

    Professor of Medicine Medical Director, Cardiac ICU Co-Director, Cardiac Catheterization Laboratory Director, Interventional Cardiology Fellowship Program
    University of Chicago Medicine
    Chicago, Illinois, United States

    Disclosure information not submitted.

  • Ramon Quesada, MD, FACP, FACC, FSCAI

    Medical Director of Interventional Cardiology, Structural Heart & Cardiac Research
    Miami Cardiac & Vascular Institute
    Miami, Florida, United States

    Disclosure(s): No financial relationships to disclose

Disclosure(s):
Timothy D. Henry, MD: No financial relationships to disclose
Jeff W. Chambers, MD, FSCAI, FACC: Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)
Michael J. Lim, MD: Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)
Ramon Quesada, MD, FACP, FACC, FSCAI: No financial relationships to disclose